DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Open-angle Glaucoma; Ocular Hypertension

Intervention: Travoprost 0.004%/timolol 0.5% ophthalmic solution (Drug); Travoprost ophthalmic solution, 0.004% (Drug); Timolol maleate ophthalmic solution, 0.5% (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Alcon Research

Official(s) and/or principal investigator(s):
Theresa Landry, Study Director, Affiliation: Alcon Research


The purpose of this study is to assess patient compliance with DuoTrav versus concomitant administration of Timolol 0. 5% plus TRAVATAN in patients with open-angle glaucoma or ocular hypertension.

Clinical Details

Official title: Compliance Study Comparing DuoTrav to TRAVATAN Plus Timolol Using the Dosing Aid

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Patient compliance


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Adult patients with open-angle glaucoma or ocular hypertension;

- Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

- Visual acuity worse than 0. 60;

- Other protocol-defined exclusion criteria may apply.

Locations and Contacts

Seattle, Seattle, Washington 98104, United States
Additional Information

Starting date: March 2007
Last updated: July 22, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017